Revised European-American Lymphoma Classification

S. A. Pileri, L. Leoncini, B. Falini

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The recently proposed Revised European-American Lymphoma Classification represents a serious attempt to overcome the controversies that have divided both pathologists and clinicians over the past three decades. It was formulated by 19 experienced hematopathologists, who agreed on a list of clinicopathologic entities, all well known from the literature and daily practice. Compared with previous schemes, the Revised European-American Lymphoma Classification offers the following advantages: 1) it incorporates all nodal and extranodal lymphoid tumors, including Hodgkin's disease; 2) it is histogenetically updated by recognizing new categories (such as the mantle cell category) and grouping tumors that need further validation to be considered as separate entities (eg, diffuse large B-cell lymphomas); 3) it avoids any morphologic grading, the clinical course of lymphomas being influenced by factors other than histology (tumor burden, cell kinetics, apoptotic rate, and so forth) and 4) it includes all molecular data (phenotype, genotype, cytogenetics, and so forth), which can assist in the diagnosis.

Original languageEnglish
Pages (from-to)401-407
Number of pages7
JournalCurrent Opinion in Oncology
Volume7
Issue number5
Publication statusPublished - 1995

Fingerprint

Lymphoma
Lymphoma, Large B-Cell, Diffuse
Tumor Burden
Hodgkin Disease
Cytogenetics
Neoplasms
Histology
Genotype
Phenotype
Pathologists

ASJC Scopus subject areas

  • Cancer Research

Cite this

Revised European-American Lymphoma Classification. / Pileri, S. A.; Leoncini, L.; Falini, B.

In: Current Opinion in Oncology, Vol. 7, No. 5, 1995, p. 401-407.

Research output: Contribution to journalArticle

Pileri, SA, Leoncini, L & Falini, B 1995, 'Revised European-American Lymphoma Classification', Current Opinion in Oncology, vol. 7, no. 5, pp. 401-407.
Pileri, S. A. ; Leoncini, L. ; Falini, B. / Revised European-American Lymphoma Classification. In: Current Opinion in Oncology. 1995 ; Vol. 7, No. 5. pp. 401-407.
@article{935265ff48c54910af2133f82845daa3,
title = "Revised European-American Lymphoma Classification",
abstract = "The recently proposed Revised European-American Lymphoma Classification represents a serious attempt to overcome the controversies that have divided both pathologists and clinicians over the past three decades. It was formulated by 19 experienced hematopathologists, who agreed on a list of clinicopathologic entities, all well known from the literature and daily practice. Compared with previous schemes, the Revised European-American Lymphoma Classification offers the following advantages: 1) it incorporates all nodal and extranodal lymphoid tumors, including Hodgkin's disease; 2) it is histogenetically updated by recognizing new categories (such as the mantle cell category) and grouping tumors that need further validation to be considered as separate entities (eg, diffuse large B-cell lymphomas); 3) it avoids any morphologic grading, the clinical course of lymphomas being influenced by factors other than histology (tumor burden, cell kinetics, apoptotic rate, and so forth) and 4) it includes all molecular data (phenotype, genotype, cytogenetics, and so forth), which can assist in the diagnosis.",
author = "Pileri, {S. A.} and L. Leoncini and B. Falini",
year = "1995",
language = "English",
volume = "7",
pages = "401--407",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Revised European-American Lymphoma Classification

AU - Pileri, S. A.

AU - Leoncini, L.

AU - Falini, B.

PY - 1995

Y1 - 1995

N2 - The recently proposed Revised European-American Lymphoma Classification represents a serious attempt to overcome the controversies that have divided both pathologists and clinicians over the past three decades. It was formulated by 19 experienced hematopathologists, who agreed on a list of clinicopathologic entities, all well known from the literature and daily practice. Compared with previous schemes, the Revised European-American Lymphoma Classification offers the following advantages: 1) it incorporates all nodal and extranodal lymphoid tumors, including Hodgkin's disease; 2) it is histogenetically updated by recognizing new categories (such as the mantle cell category) and grouping tumors that need further validation to be considered as separate entities (eg, diffuse large B-cell lymphomas); 3) it avoids any morphologic grading, the clinical course of lymphomas being influenced by factors other than histology (tumor burden, cell kinetics, apoptotic rate, and so forth) and 4) it includes all molecular data (phenotype, genotype, cytogenetics, and so forth), which can assist in the diagnosis.

AB - The recently proposed Revised European-American Lymphoma Classification represents a serious attempt to overcome the controversies that have divided both pathologists and clinicians over the past three decades. It was formulated by 19 experienced hematopathologists, who agreed on a list of clinicopathologic entities, all well known from the literature and daily practice. Compared with previous schemes, the Revised European-American Lymphoma Classification offers the following advantages: 1) it incorporates all nodal and extranodal lymphoid tumors, including Hodgkin's disease; 2) it is histogenetically updated by recognizing new categories (such as the mantle cell category) and grouping tumors that need further validation to be considered as separate entities (eg, diffuse large B-cell lymphomas); 3) it avoids any morphologic grading, the clinical course of lymphomas being influenced by factors other than histology (tumor burden, cell kinetics, apoptotic rate, and so forth) and 4) it includes all molecular data (phenotype, genotype, cytogenetics, and so forth), which can assist in the diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=0028979010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028979010&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 401

EP - 407

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 5

ER -